Matrix Dynamics is a service run out of the Barts Cancer Institute, Queen Mary University of London, offering preclinical assays in a patient tissue-derived 3D tumour model.
Matrix Dynamics is committed to accelerating the development of immunotherapy drugs. Our Dynamic In Vitro Assay (DIVA) platform recapitulates the immunosuppressive microenvironment characteristic of solid tumours, enabling accurate and efficient development of immunotherapies. By offering both in-house and contract research services, we support pharmaceutical companies and academic researchers in bringing novel treatments to market more quickly and effectively.
Our multidisciplinary team at Barts Cancer Institute, QMUL, has extensive expertise in immuno-oncology, tissue engineering, and glycobiology. We aim to establish our technology as the gold standard for preclinical immuno-oncology studies and offer specialised expertise in tumour microenvironment target discovery to accelerate immunotherapy drug development.
How our model works
Our Dynamic In Vitro Assay (DIVA) platform provides a physiologically relevant disease model due to its success in maintaining the structural and immunosuppressive properties of solid tumours and its ability to measure several parameters in parallel.
DIVA consists of a series of semi-high-throughput assays run in decellularised tissue models of various types including breast, ovarian, pancreatic, and neuroblastoma cancer. Tissues are decellularised to yield the sample’s extracellular matrix (ECM), which has been shown to be a key driver of resistance to immunotherapy.
Following decellularisation, the ECM can be re-populated with cancer cell lines, macrophages, T Cells, fibroblasts and other cell therapies, providing a bespoke model tailored to partners’ experimental requirements.
In parallel, tissues are characterised using either a multi-omics or histopathology approach, enabling the team to develop profile libraries of patient material and relate data back to assay results.
